Ethambutol/isoniazid/pyrazinamide/rifmapicin nanoparticles - Lifecare Innovations

Drug Profile

Ethambutol/isoniazid/pyrazinamide/rifmapicin nanoparticles - Lifecare Innovations

Latest Information Update: 28 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lifecare Innovations
  • Class Antituberculars; Ethylenediamines; Hydrazines; Rifamycins
  • Mechanism of Action Cell wall inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Tuberculosis

Most Recent Events

  • 25 Nov 2016 Lifecare Innovations plan a phase I trial in Volunteers in India (CTRI-2016-10-007356)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top